These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 15629202

  • 1. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders.
    Youdim MB, Buccafusco JJ.
    Trends Pharmacol Sci; 2005 Jan; 26(1):27-35. PubMed ID: 15629202
    [Abstract] [Full Text] [Related]

  • 2. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
    Barchet TM, Amiji MM.
    Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
    [Abstract] [Full Text] [Related]

  • 3. CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases.
    Youdim MB, Buccafusco JJ.
    J Neural Transm (Vienna); 2005 Apr; 112(4):519-37. PubMed ID: 15666041
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases.
    Mandel S, Youdim MB.
    Free Radic Biol Med; 2004 Aug 01; 37(3):304-17. PubMed ID: 15223064
    [Abstract] [Full Text] [Related]

  • 7. Polycyclic cage structures as lipophilic scaffolds for neuroactive drugs.
    Joubert J, Geldenhuys WJ, Van der Schyf CJ, Oliver DW, Kruger HG, Govender T, Malan SF.
    ChemMedChem; 2012 Mar 05; 7(3):375-84. PubMed ID: 22307951
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec 05; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Ubiquitin proteasome system as a pharmacological target in neurodegeneration.
    Hol EM, Fischer DF, Ovaa H, Scheper W.
    Expert Rev Neurother; 2006 Sep 05; 6(9):1337-47. PubMed ID: 17009921
    [Abstract] [Full Text] [Related]

  • 14. Neuroprotection from complement-mediated inflammatory damage.
    Kulkarni AP, Kellaway LA, Lahiri DK, Kotwal GJ.
    Ann N Y Acad Sci; 2004 Dec 05; 1035():147-64. PubMed ID: 15681806
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders.
    Geldenhuys WJ, Van der Schyf CJ.
    Expert Opin Drug Discov; 2013 Feb 05; 8(2):115-29. PubMed ID: 23231597
    [Abstract] [Full Text] [Related]

  • 19. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
    Sas K, Robotka H, Toldi J, Vécsei L.
    J Neurol Sci; 2007 Jun 15; 257(1-2):221-39. PubMed ID: 17462670
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.